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Objective:  To  understand  the  values  attached  to cancer  treatment  at the  end of life  (EoL)  to  inform  policy
decisions  around  the  Cancer  Drugs  Fund  (CDF)  and  the  National  Institute  for Health  and  Care  Excellence
(NICE)  EoL  criterion.
Design: Semi-structured  interviews  with  patients  and health  professionals.
Purposive recruitment  was  performed  iteratively  alongside  analysis  of interview  transcripts  using
constant  comparison.
Participants:  Patients  with  incurable  prostate  and  colorectal  cancer  (n  =  22)  who  received  drugs  funded
through  the CDF  and  oncologists  and  palliative  care  professionals  (n =  16) treating  patients  on  CDF  drugs.
Results:  While  the  majority  of  patient  and  oncologist  participants  expressed  gratitude  for  access  to the
CDF,  some  patient  participants  reported  experiencing  a sense  of guilt,  and  many  oncologists  admitted  to
concern  about  the  justice  of  a ring-fenced  fund  solely  for anti-cancer  drugs.  For  patient  and  professional
participants,  cancer  drugs  were  not  necessarily  seen as a funding  priority  over other  calls  on  the  NHS
purse.  Overall,  patients  and  health  professionals  emphasised  prioritising  quality  over  quantity  at  the  end
of  life,  with  only  a minority  describing  improved  quality  of  life  at  the  end  of  life  which  added  value.
Conclusion:  While  patients  and  oncologists  appreciated  the  drugs  available  through  the  CDF,  most
expressed  concern  about  its  fairness.  Competing  participant  views  about  the  added  value  of  the  end
of  life  is  challenging  for  resource  allocation.
© 2019  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Between 2000 and 2018, 305 anti-cancer drug decisions were
ublished by the National Institute for Health and Care Excellence
NICE) which, based on the drugs’ clinical and cost-effectiveness,
ecommended (or not) their use in the National Health Service
NHS) in England and Wales [1]. NICE assesses the value of a tech-
ology using a cost utility approach (cost per quality adjusted lifePlease cite this article in press as: Chamberlain C, et al. “W
tion”: A qualitative study of patients and their health professi
https://doi.org/10.1016/j.healthpol.2019.05.022
ear [QALY]) and combines this ﬁnding with social value judge-
ents, identiﬁed by the NICE Citizens Council (established in 2002)
2,3], In 2009, NICE introduced a speciﬁc end of life (EoL) crite-
∗ Corresponding author at: Rm 3.12, Canynge Hall, Bristol Medical School, 39
hatley Rd, Bristol, BS8 2PS, UK.
E-mail addresses: Charlotte.Chamberlain@bristol.ac.uk, ccham@doctors.org.uk
C. Chamberlain), A.Owen-Smith@bristol.ac.uk (A. Owen-Smith),
iona.Mackichan@bristol.ac.uk (F. MacKichan), Jenny.Donovan@bristol.ac.uk
J.L. Donovan), William.Hollingworth@bristol.ac.uk (W.  Hollingworth).
ttps://doi.org/10.1016/j.healthpol.2019.05.022
168-8510/© 2019 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
rion: that drugs used to extend life (by three months or more) in
the last two  years of life (in small patient populations) could be
increased (in practice up to £50,000 per QALY) [4]. This is compared
with the usual cost-effective threshold applied to other technolo-
gies of £20-£30,000 per year of quality life year gained [5]. All 66
NICE recommendations which cite the EoL criterion are for can-
cerous or precancerous conditions [6]. The EoL criterion has been
cited as a “positive access driver for treatments”, speciﬁcally for
those drugs lacking phase 3 data required for other drug approvals
[7]. In other words, the current use of the EoL criterion exclusively
for anti-cancer drugs and the potentially lower evidence threshold
required for the EoL criterion are two  ways in which anti-cancer
drugs arguably receive ‘special treatment’ compared with other
pharmaceuticals and other health technologies.hat’s fair to an individual is not always fair to a popula-
onals using the Cancer Drugs Fund. Health Policy (2019),
A subsequent policy endeavour in England that facilitated access
to anti-cancer drugs at the end of life was the Cancer Drugs Fund
(CDF). The CDF was established in 2010 as a ring-fenced fund for
cancer pharmaceuticals which NICE had either not recommended
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ue to poor cost effectiveness or had not evaluated. In reality, the
DF provided access to drugs for patients with incurable cancer,
here treatment was too costly even within the extended NICE
hreshold for the EoL criterion [8]. The CDF consistently overspent
espite receiving an annually increasing budget, additional top-up
unds and introducing prioritisation criteria to rationalise funded
reatments. In 2016 responsibility for anti-cancer drug funding
ecision making returned to NICE, overturning the independence
t had enjoyed as a ring-fenced fund under the oversight of NHS
ngland.
The six-year CDF policy experiment has since been discredited
y a number of sources. It has been criticised for delivering poor
alue for tax payers through a net health loss for the population,
oth as a result of the lost opportunity of this money for spend-
ng in other areas of the NHS, and for failing to fund drugs which
epresented ‘meaningful clinical beneﬁt’ according to validated
nternational scales [9]. It also provided scant evidence to advance
nderstanding of the use of high-cost anti-cancer drugs in incurable
ancer [10]. Even now that the CDF is under the NICE umbrella for
ecision making, it faces persistent criticism that its current form
ermits drugs with a lower threshold of evidence to enter the mar-
et compared with the processes established for drugs for other
iseases [11]. Whether these different policy approaches for anti-
ancer drugs reﬂect actual public priorities for added value of life
t the end of life, added value for cancer treatments, or neither,
s unclear, [12–19]. The largest systematic review investigating
he value attributed to cancer by the public found no ‘consistent
upport’ for greater value for health gains in patients with cancer
compared with patients without cancer) [20]. Others studies have
ound little evidence of support for giving priority to end of life
reatments [19]. Valuing anti-cancer drugs at the end of life above
ther drugs in the NHS, during the time of the CDF’s operation as
n autonomous ring-fenced fund, but prior to its transition into a
anaged access fund is explored in this manuscript. This study uses
emi-structured interviews to investigate professional and patient
iews about funding for cancer care and whether cancer and the
nd of life should have greater value in funding compared with
ther diseases.
. Methods
.1. Design
Face-to-face audio-recorded semi-structured interviews were
ndertaken with patients with incurable colorectal and prostate
ancer, and oncology and palliative care consultants in the South-
est region of England. This study is reported in line with the
onsolidated criteria for reporting qualitative studies (COREQ) [21]
nd was approved by the SW Ethics committee in 2013 (REC refer-
nce 13/SW/0007).
.2. Sampling and recruitment
Purposive sampling was employed to recruit patients with
rostate and colorectal cancer who were taking drugs prescribed on
he CDF. Prostate cancer is a common cancer and speciﬁc prostate
ancer treatments were listed in the top ﬁve most commonly pre-
cribed drugs on the CDF at the time of interview [22]. Patients with
olorectal cancer were recruited as a comparative case study due
o differences in the treatment regime (intravenous as opposed to
ral) as well as an opportunity to compare gender perspectives.Please cite this article in press as: Chamberlain C, et al. “W
tion”: A qualitative study of patients and their health profess
https://doi.org/10.1016/j.healthpol.2019.05.022
olorectal cancer accounted for two of the ﬁve most commonly
rescribed anti-cancer agents on the CDF in this period.
Oncologists were sampled as the main professional group refer-
ing patients on a case-by-case basis for life-extending anti-cancer PRESS
olicy xxx (2019) xxx–xxx
drug therapy on the CDF. Palliative care consultants are involved in
Multi-Disciplinary Team Meetings (MDT) decisions about the eli-
gibility of a patient for drugs available through the CDF. A number
of patients seen by palliative care will have accessed drugs through
the CDF. Palliative care specialism in care of patients at the end of
life means they have a unique perspective on the value of life at the
end of life.
Patients were purposively sampled from one teaching and one
district general hospital and health professionals from three district
and one teaching hospital in one region of England. Eligible patients
(i.e. those receiving CDF drugs for prostate or colorectal cancer)
were identiﬁed by clinicians at out-patient clinics (and one patient
through the chemotherapy day unit). Sampling was done in a step-
wise fashion: data gathering, followed by data analysis, followed by
more data gathering [23]. Once no new data themes were emerging
from the patients with prostate cancer from a teaching hospital
setting, a comparator group of patients with prostate cancer were
purposively recruited from a district general hospital setting, along
with patients with colorectal cancer as comparative groups.
Professional participants were identiﬁed by checking hospital
websites and cross-checking specialty information with the switch-
board at each trust. Invitations to participate were sent by email
and letter, to all oncologists (colorectal and urological subspecial-
ties) and all palliative care consultants. A single reminder was sent
after approximately one month of no response.
2.3. Data generation
Interviews took place between April 1st 2013 and December
1st 2014 at patients’ homes (20/22), at the hospital following an
out-patient appointment (one) or at the university (one). Patient
participant interviews most commonly took place with a spouse or
other family member present (17/22). Professional interviews were
conducted over the same period in the participants’ place of work
(hospice or hospital 15/16) or the consultant’s home (1/16). Unob-
trusive digital audio-recording was used for all interviews. The
same researcher (CC) conducted all interviews and audio-recorded
reﬂective ﬁeld notes. The topic guide was  generated in consultation
with two experienced qualitative researchers and the PPI represen-
tative (AOS, JD, CH) and then adjusted on three separate occasions
to probe emerging themes more effectively.
For some questions, an explanation of the CDF or the NICE EoL
criterion was  required before the participant could discuss their
understanding of the value of the organisation or criteria. These
explanations were short, generic, and prepared in advance with co-
author consultation to avoid undue inﬂuence on the data collected.
All participants in this study received written information
before agreeing to participate and provided written consent before
recording commenced. No participants declined being recorded. All
audio-recordings were transcribed verbatim, using standard nota-
tion, by the same experienced transcriber. Transcripts were read in
conjunction with audio-recordings to ensure quality of transcrip-
tion (CC). Participant checking of the transcripts or of the ﬁndings
was not undertaken due to the emotional nature of the interviews
for patients and time pressures of professional participants.
2.4. Analysis
Analysis was based on a grounded theory approach with induc-
tive generation of hypotheses [24]. Line by line coding of the
transcribed data identiﬁed key themes [23]. Coding structures were
recorded in NVivo software. Of the 38 interviews read and coded byhat’s fair to an individual is not always fair to a popula-
ionals using the Cancer Drugs Fund. Health Policy (2019),
CC, eight (21%) were read and coded independently by supervisors
(JD, AOS) to assess consistency in coding and emergent themes.
Coding discrepancies were discussed, and agreement reached.
Themes were compared with each other and with older and newer
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Table  1
Patient participants.
ID (n = 22) Age range Sex Site Cancer Type Cancer diagnosis (years) Prior chemo-therapy Drug and duration (weeks)
Mr  X 70-75 M TH Prostate 15 Y Enzalutamide: 40
Mr  P 65-70 M TH Prostate 13 Y Enzalutamide: 4
Mr  D 60-65 M TH Prostate 11 N Abiraterone: UD
Enzalutamide: 6
Mr  Y 80-85 M TH Prostate 10 N Abiraterone: 12
Mr  N 70-75 M TH Prostate 10 Y Radium 223: 3rd cycle
Mr  A 80-85 M DGH Prostate 10 N Abiraterone: 52
Mr  M 75-80 M TH Prostate 6 N Abiraterone: UD
Mr  T 70-75 M TH Prostate 6 N Abiraterone: 16
Mr  Q 65-70 M TH Prostate 5 N Enzalutamide-Bicalutamide
trial (blinded): 81
Abiraterone: 20
Mr  O 85-90 M TH Prostate 4 N Abiraterone: 6
Mr  I 70-75 M DGH Prostate 4 Y Enzalutamide: 51
Mr  J 55-60 M DGH Prostate 4 Y Radium 223: 1st cycle
Mr  R 70-75 M DGH Prostate 3 Y Enzalutamide: 12
Cabazitaxel: 10 cycles
Mr  S 70-75 M TH Prostate 3 Y Enzalutamide: 8
Mr  V 65-70 M DGH Prostate 2.8 Y Enzalutamide: 12
Mr  K 70-75 M DGH Prostate 2 Y Enzalutamide: 6
Mr  C 75-80 M DGH Prostate 2 Y Enzalutamide: 3
Mr  F 65-70 M DGH Prostate 1.9 N Enzalutamide: 1
Mr  U 80-85 M TH Prostate 1.5 N Abiraterone: 4
Mrs  L 50-55 F DGH Colorectal 4 Y- ongoing Cetuximab: 24
Mr  E 70-75 M TH Colorectal 3 Y- ongoing Bevacizumab: 20
soon to start Cetuximab
Mrs  B 50-55 F DGH Colorectal 2 Y- ongoing Cetuximab: 12 cycles
Bevacizumab: 4
U
d
c
o
D
i
o
w
s
w
3
t
3
1
d
r
v
e
d
A
4
3
ﬁ
(
s
wD: Undisclosed duration, TH: Teaching hospital, DGH: District general hospital.
ata, identifying dissonant views and deﬁning higher theoreti-
al categories. Data analysis was iterative, using the technique
f constant comparison to deﬁne and reﬁne emergent themes.
ata counts have been predominantly represented with words, for
nstance, ‘several’, ‘the majority’ in keeping with the narrative style
f the results. However, some numerical counts have been included
here this adds meaning. Reﬂexivity: data collection and analysis
hould be viewed in the context of a female, health professional
ith experience in public health and palliative medicine.
. Results
Patient (Table 1) and professional (Table 2) participant charac-
eristics.
.1. Patient participant characteristics
Twenty-one patients with prostate cancer agreed to interview:
9 of whom were interviewed (one was not interviewed due to
eteriorating health and another due to loss of contact). Ages
anged from 59 to 85 years (typical for this cancer type) with inter-
iews between 31 min  and one hour and 47 min.
Seven patients with colorectal cancer agreed to interview, how-
ver only three patients were able to participate (two withdrew
ue to ill health and two did not respond after initial agreement).
ges ranged from 54 to 71 years. Interview duration ranged from
1 min  to one hour 18 min.
.2. Health professional participant characteristics
21 health professionals responded to the study invitation, butPlease cite this article in press as: Chamberlain C, et al. “W
tion”: A qualitative study of patients and their health professi
https://doi.org/10.1016/j.healthpol.2019.05.022
ve responders were not interviewed due to: moved out of area
one); wrong sub-specialty recorded (one); failure to respond to
ubsequent contact (one); time pressures (one); and feeling they
ould have nothing to contribute (one). Sixteen health professionalinterviews were conducted ranging from 31 min  to one hour six
minutes.
3.3. Emergent themes
Three major themes were identiﬁed in the data and these are
now described in more detail with the use of patient participant
and health professional participant quotes.
3.3.1. Resource allocation in the NHS
Patient participants expressed gratitude for having access to the
CDF. Three patient participants acknowledged from the start of the
interview that the NHS had to make tough choices due to its lim-
ited resource in a context of increasing demand. However, patient
views diverged amongst those participants who accepted that some
treatments were not affordable on the NHS and those who  believed
that human life was  too valuable to ration in any way.
“There’s always going to be this tension between what’s available
and what we can afford.  . .I  realise that there are limits, you know.
. . .Oh well I’ve got it, blow everyone else, but it’s not like that, is
it?”
[Mr X, 74 years old, 15 years with prostate cancer]
“We’ve paid all our working lives (pause), you know, deﬁnitely
there should be the budget there. . .”
[Mrs B, 55 years old, two years with colorectal cancer]
On the other hand, professional participants universally
accepted that rationing takes place, but generally described
resource allocation decision making as “too difﬁcult” for them (four
palliative care consultants, two  oncologists). Therefore, when asked
to describe priorities for the £200 million allocated to the Cancerhat’s fair to an individual is not always fair to a popula-
onals using the Cancer Drugs Fund. Health Policy (2019),
Drugs Fund (at the time of interview), many were reluctant to com-
ment. Interviewees struggled to reconcile the ‘patient in front of
them’ with population justice and resource allocation decisions for
patients with terminal cancer.
ARTICLE IN PRESSG ModelHEAP-4097; No. of Pages 7
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Table  2
Health professional participants.
ID (n = 16) Speciality Years a consultant> or ≤ 10 years Sex Practice setting*
Dr M OncColo ≤ F DGH
Dr  H OncColo ≤ F DGH
Dr  Y OncColo > M DGH
Dr  X OncColo > F DGH
Dr  A OncColo > M TH
Dr  C OncColo > F TH
Dr  D OncUrol > M TH
Dr  B OncUrol ≤ F TH
Dr  I OncUrol ≤ F DGH
Dr  G OncUrol > F DGH
Dr  E Palliative ≤ F TH
Dr  Z Palliative > F TH
Dr  L Palliative ≤ F TH
Dr  Q Palliative > F Community
Dr  P Palliative ≤ F Community
Dr  O Palliative > F DGH
re and
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o* These denote the most common practice settings, although some palliative ca
ommunity and DGH).
“. . . what’s fair to an individual is not always fair to a popula-
tion. . ..”
[Dr B, urological oncologist]
“I try not to think about it too much because I’m not clever enough
to work out how you fund everything within the NHS with the drugs
and the budgets that you have available. . .I just concentrate on my
patients who  I see beneﬁts for.”
[Dr I, urological oncologist]
.3.1.1. Unacknowledged preference for cancer?. Patient partici-
ants recognised a cultural anxiety around cancer meaning that it
as promoted above other diseases, inﬂuencing greater demand
or political action and treatment. The fear of cancer’s insidious
nset and the sense it was unavoidable or random, with limited
reatment options, was felt to inﬂuence funding decision making.
“. . ..Cancer’s something you fall foul of which heart disease, fair
enough it can be hereditary but by and large it’s done through your
own fault. . .”
[Mr  N, 73 years old, ten years with prostate cancer]
However, despite this acknowledgment, the majority [15] of
atient participants did not feel that cancer warranted prioritisa-
ion in resource allocation decision making.
“. . .somebody that’s got a heart problem obviously they proba-
bly think the same way as I do. They’re frightened to death and if
they can’t get something from the funding then it’s like well you’re
playing with my  life.  . .”
[Mrs L, 54 years old, four years with colorectal cancer]
Although most clinician participants described a sense of
nequity around the prioritisation of cancer above other diseases,
ome explained potential reasons for its extra investment being
 reﬂection of public values and the ‘emotive’ nature of cancer
two oncologists, three palliative care); the inﬂuence of the media
two oncologists, two palliative care); an expression of the historic
nder-funding of anti-cancer drugs (two oncologists); a represen-
ation of the signiﬁcant burden it presents in terms of morbidity and
ortality (two oncologists), or perhaps just ‘politics’(four oncology,
ne palliative medicine).
“if there’s two boxes for collection and one says COPD and the othersPlease cite this article in press as: Chamberlain C, et al. “W
tion”: A qualitative study of patients and their health profess
https://doi.org/10.1016/j.healthpol.2019.05.022
says cancer, people will give to the cancer, um, because its very
emotive, isn’t it, but more people die without cancer than with
cancer but the funding is very skewed.”
[Dr Q, consultant in palliative medicine] oncology professionals practiced across more than one site (e.g. DGH and TH or
3.3.2. The trade-off between individual and population justice:
the perceived strengths and weaknesses of the CDF
Despite all patient participants’ treatments having been funded
by the CDF, only eight of the 22 (36%) had any knowledge of its
existence. Seven participants recalled a conversation with their
consultant and one had heard about it through the media. How-
ever, several patient participants (3/22) expressed guilt in their use
of the high cost drugs through the CDF, feeling it was ‘selﬁsh’. Two
other participants described the potential that they may be accused
of being ‘selﬁsh’ but that they deserved the drugs (“I’m worth it”).
“Well, that [the CDF is ring-fenced money for cancer] could make
one feel selﬁsh. Oh I’m alright Jack, but what about the people
coming along. . .I  would like to think that it was available for every-
body.”
[Mr  O, 85 years old, four years with prostate cancer]
Health professionals were all familiar with the CDF and articu-
lated a similar conﬂict to patients in its use. Concern around the
CDF and its use was expressed in two ways: ﬁrstly, two oncol-
ogy participants commented on the guilt they had felt in the past
as a result of the ‘postcode lottery’ in prescribing or the inequal-
ity of access between private and NHS care- a guilt that had been
improved with the CDF. Conversely, the majority expressed signif-
icant concern about access to the CDF in its current form, due to a
sense it was a poor use of resource for the population.
“I don’t think it is fair necessarily [the CDF] . . .”
[Dr L, Palliative care consultant]
Health professional participants clearly articulated both
strengths and weaknesses of the CDF. The general strengths of the
CDF being: greater access to anti-cancer drugs; potential respon-
siveness to the needs of rare cancers and reduced clinical practice
variation. However, professional participants also criticised the CDF
for its potential to undermine and duplicate NICE processes, reduc-
ing clinical discretion in prescribing. The most frequent arguments
expressed against the CDF included its effect on the generation
of evidence. Three oncologists and two  palliative care participants
were disappointed that the CDF did not provide a greater evidence
base towards improving care for patients in the future. Not only
was there a criticism of the usefulness of the data for informing
better cancer care in the future, but two  oncologists felt there was
a danger that the introduction of the CDF may reduce the drivehat’s fair to an individual is not always fair to a popula-
ionals using the Cancer Drugs Fund. Health Policy (2019),
to perform clinical trials and therefore, further reduce the qual-
ity of evidence to improve care in the future for the population.
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Table  3
The trade-off between individual and population justice: the perceived strengths
and weaknesses of the CDF.
“Whereas before the [CDF] there was a huge discrepancy between private and
NHS.  . .[after] that really changed.”
[Dr C, colorectal oncologist]
“. . .People with very unusual diseases who needed very high cost drugs. . .for that
group [care] has been revolutionised by the Cancer Drugs Fund. . .”
[Dr A, colorectal oncologist]
“The downside has been that it’s [the CDF] completely neutered NICE. . .”
[Dr  A, colorectal oncologist]
“. . .with the CDF becoming so prescriptive, the CDF has started to dictate
practice.  . .”
[Dr H, colorectal oncologist]
“I suspect that people would feel happier if we had some process where we  actively
recorded what happened to these patients [on the CDF] because. . .nobody really
is  following up what’s happening.  . .”
[Dr G, urological oncologist]
Table 4
Value at the end of life.
“Well I ﬁnd it [EoL criterion] quite controversial. . .because at the end of the day, as
I’ve just said, it’s not so much about extending life, it’s the quality of life. There’s
no  point someone saying well you can live for two years but life’s going to be a
living hell. . .”
[Mr I, 72 years old, four years with prostate cancer]
“it’s a nonsense that you would give more value to something that is going to
extend a life by two weeks than you would give to something that might
improve a quality of life. . .for twenty years. . .you might say, but if you’re dying,
two weeks.  . .[is]priceless. It’s not. It’s only priceless if you use that two weeks to
put  your affairs in order. . . but. . .because they will be having those extra two
weeks on a cancer drug, they’re not going to use it to write a will, etcetera. . . I
think cancer drugs add to the whole kind of death denial.  . .”
[Dr E, palliative care consultant]
“. . .It may  sound clichéd but life has a different intensity when you know. . .your
inevitable demise and roughly when that might be.  . .each day now. . .is more
important to me  than a day six years ago [pre-diagnosis]. . . knowing that, it
becomes a more intense way of living, I see the value in it. . . [I] support that
[EoL criterion].”
[Mr Q, 65 years old, ﬁve years with prostate cancer]
“.  . .I  build things in Meccano on a construction of systems. . .there may  come a
point where I can’t do [cycling] but I may still be able to have manipulative
skills.  . .I’ve stacked up lots of ﬁlms I’ve always wanted to see and I’ve got them
on  DVD so when I’m a bit more gaga. . . so I’m sort of metering these things out
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gas  to what I’ll do as the situation demands.”
[Mr Q, 65 years old, ﬁve years with prostate cancer]
Table 3: Participant quotes on the strengths and weaknesses of
he CDF).
.3.3. Value at the end of life
Debates over whether life ‘at the end of life’ (as deﬁned by NICE)
s more valuable than life before a diagnosis of terminal cancer
ed to most patient and professional participants emphasising that
alue at the end of life was determined by the quality of that life.
owever, one patient, who described being in severe pain with his
ancer, felt motivated by the opportunity to be alive longer with
is family despite describing his life as poor quality. While the pre-
minence of maintaining quality of life rather than quantity was
lmost universal amongst all participants, there was  considerable
ebate over the evolving nature of quality of life, where participants
dapt to changing expectations of physical function, for instance.
Table 4 Value at the end of life participant quotes)
.3.3.1. The value of the end of life for a population. There are impor-
ant population implications arising from valuing the end of life
igher than other times of life. For instance, having a more accessi-Please cite this article in press as: Chamberlain C, et al. “W
tion”: A qualitative study of patients and their health professi
https://doi.org/10.1016/j.healthpol.2019.05.022
le NICE threshold for expensive drugs through the EoL criterion
as an opportunity cost attached for other health spend. Most
nterviewed palliative care and oncology consultants described
enerally poorer quality of life at the end of life. Therefore, priori- PRESS
olicy xxx (2019) xxx–xxx 5
tising that time- over other times, was  considered poor value for
the individual, but also for society, where the money could have
been spent supporting patients to access treatments that provided
quality of life before they became so unwell at the end of life.
“. . .if  you can keep a patient. . . in their sixties, working and having
a normal life with metastatic disease, isn’t that more valuable to
society than waiting until they’re within two years of death [to
prioritise their treatment].”
[Dr I, urological oncologist]
There was also a pragmatic concern raised by participants (one
patient and several professional participants) around the feasibil-
ity of valuing time at the end of life compared with other times in
life, when identifying the end of life prospectively was not easy.
Participants expressed concern at how the uncertainty of identify-
ing time at the end of life in medical practice could translate into
policies that were challenging to fairly enforce.
3.3.3.2. The dissonance. Three oncologists and two  palliative care
physicians disagreed with the majority of clinicians, feeling that
time at the end of life may  have added value for some individuals,
despite any personal costs in terms of added time spent in hospital
and potential treatment side effects and complications. Many clin-
icians recognised that for patients, all life, and in particular their
last months of life, has immeasurable worth to the individual and
their family and therefore there was a dissonance between their
thinking about the individual patient and the NHS population with
cancer as a whole. Of those participants describing this apparent
conﬂict between the value of time at the end of life for the popula-
tion and for the individual, one palliative care participant and one
oncology participant cited examples of young patients or young
families having greater value at the end of life, therefore there may
be a conscious or subconscious context to the clinician responses
where individuals at the end of life in this context (young) may  be
perceived to have added value.
“. . .[a] very expensive treatment [with].  . .life prolongation of six
to eight weeks.  . .doesn’t seem to be a good use of money, but if you
said that to me when I had somebody in front of me  who had young
children I would probably feel very, very differently”
[Dr O, palliative care consultant]
4. Discussion
Patient participants shared a sensation of concern or guilt
around being treated differently through the CDF. Oncologists
expressed concern at their personal conﬂict between appreciat-
ing access to anti-cancer drugs through the CDF, while admitting
this may  be unfair for the population. Oncology and palliative care
consultants shared common ground in ﬁnding resource allocation
decision making challenging (15/16) and the vast majority con-
curred that the value of life at the end of life was no greater than
at other times of life: value was determined by quality. However,
deﬁning the changing quality of life in incurable cancer was seen
as complex and several participating clinicians admitted to feel-
ing time at the end of life, for some individuals, may  have greater
importance. Several patient participants also felt strongly that the
end of life had greater value compared with other times of life,
in spite of their increased physical limitations. Therefore, there
were differing views amongst professionals and amongst patients
around the value of time at the end of life.hat’s fair to an individual is not always fair to a popula-
onals using the Cancer Drugs Fund. Health Policy (2019),
4.1. Comparison with the literature
These interviews reinforced the ﬁnding that health profession-
als were uncomfortable practicing prioritisation decision making
 ING ModelH
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25]. There is no literature speciﬁcally around the perceptions of
he CDF and its role in funding anti-cancer drugs at the end of life
n the UK for patients or professionals with which to compare our
ndings. However, comparison has been made here with the lit-
rature around the value of cancer prioritisation and the value of
he end of life separately. In 2017 a systematic review concluded
hat there was “no consistent support for a preference for health
ains to cancer patients” [20]. This was also articulated by the vast
ajority of professional and patient participants in this work. A
ross-European study in 2014 described ﬁve predominant narra-
ives in the prioritisation debate, of which three were articulated
y our study participants. Themes of the value of all life (“the intrin-
ic value of life”) and the preeminence of quality of life (“Quality
f life is more important than simply staying alive”), as well as the
mportance of population justice (“Egalitarianism and equality of
ccess”) emerged from a number of our professional and patient
nterviews. Other emergent themes in the cross-European study
hich were not speciﬁcally probed in our interviews included “fair
nnings” and “severity” [26].
Findings from empirical research about the value of the end
f life demonstrate signiﬁcant heterogeneity and vary according
o the population sampled and the methodology used [12–19,26].
owever, the conﬂicting views presented in the literature were
ll described by participants in a single, well-conducted study by
cHugh et al, who summarized the divergent views as follows:
1) all life-extending treatments should be made available
2) there is a trade-off between making effective treatment avail-
ble and understanding that there is ﬁnite resource, where social
alue judgements should be considered
or 3) a combination of 1 and 2 which emphasizes the role of
uality of life [14].
Interviews with patients and professionals in this study reiter-
ted these divergent views. Professional participants in our study
escribed the importance of both social value judgements and qual-
ty of life in prioritisation decision making and a small number of
atients expressed a belief that all life-extending treatments should
e made available.
Integrating themes around the value of the end of life with
hemes for the value of cancer prioritisation in decision making
s relevant in the policy context of the CDF and the NICE EoL crite-
ion. The literature ﬁndings in both domains share themes around
he value of quality of life (although how to measure it is not clear)
nd the importance of considering social value judgements (such as
quity) in all prioritisation decisions whether for end of life or can-
er. Participants in this study shared similarly diverse viewpoints
s found in the literature, with the majority reinforcing ﬁndings
round the value of quality of life over quantity and the value of
quity over the preeminence of any disease type per se. The views
f a smaller number of participants – both health professionals
nd patients - who noted the less commonly held view that there
ay  be quality in life which has equivalent or greater importance,
espite physical limitations, at the end of life need to be considered
n population decision making.
.2. Strengths and limitations of the work
This study was limited by being focused on only two  cancer
ypes and primarily prostate cancer, and therefore the ﬁndings may
ot be transferable to other types of incurable cancer or other incur-
ble diseases. Importantly, metastatic prostate cancer has a longer
urvival time than other metastatic cancers and therefore poten-
ially a longer time frame to adjust expectations and reﬂect on thePlease cite this article in press as: Chamberlain C, et al. “W
tion”: A qualitative study of patients and their health profess
https://doi.org/10.1016/j.healthpol.2019.05.022
alue and deﬁnition of the end of life. Prostate cancer treatments
n the CDF were also predominantly oral (three patients were tak-
ng intravenous CDF prostate cancer treatments) and this may  have
ad an impact on quality of life different from other cancer types. PRESS
olicy xxx (2019) xxx–xxx
It was difﬁcult to recruit patients with colorectal cancer, in part
because of their greater morbidity during anti-cancer therapy for
metastatic disease, as described by their clinicians, and apparently
stronger gatekeeping amongst the health professionals. Gatekeep-
ing in palliative care research is common with the most common
health professional barrier being a ‘fear of burdening vulnerable
patients’ [27]. All patient participants were on CDF treatments and
therefore we cannot generalise themes from these participants to
those patients who were eligible for, but elected not to take CDF
drugs and therefore may  profess different feelings about the CDF
and the value of the end of life. Clinicians advising the study group
felt they had no patients who  fell into the latter category of patients
declining CDF treatment. It is also plausible that consciously or
unconsciously, oncologists selected patients for invitation to the
study based on particular views on cancer care which could limit
the generalisability of our ﬁndings. However, participants shared a
diverse range of views and emergent themes.
There is growing recognition of the need to understand and
be able to measure the value of life at the end of life to inform
policy decision making [28]. This work contributes to that litera-
ture. This research is unique in gathering patient and professional
experiences of using the CDF. The work was conducted rigorously
with dual coding of a sample of transcripts and analysis using
constant comparison techniques. Recruitment took place across
different settings (a teaching and district hospital for patients and
three district and one teaching hospitals for health profession-
als).
4.3. Implications for research and practice
2016 saw signiﬁcant change in cancer policy. The small patient
population criterion (of no more than 7000 eligible patients) to be
eligible for the NICE End of Life criteria was removed [29], and
the CDF was reabsorbed into NICE as a managed access fund. As
a managed access fund, a conditional recommendation can be pro-
vided by NICE so that a drug may  be accessed through the CDF  for
a predetermined period of up to two years while further evidence
is gathered for appraisal towards routine commissioning or rejec-
tion [30]. It is important to reﬂect on the apparent values which
underpinned the CDF and the EoL criterion- e.g. a pre-eminence of
cancer at the end of life and consider how these values continue to
inﬂuence prioritisation decision making today. The prioritisation
of cancer above other health states is not justiﬁed based on the
vast majority of participant perspectives from this study, despite
participants being able to rationalise the reasons why cancer has
traditionally been a greater focus for health spending. Ongoing
prioritisation of anti-cancer drugs, over other drugs, through the
facilitation of their entry to the market without equivalent trial
evidence as for other drugs is also called into question by these
expressed value judgements. The Health Select Committee stated
“We  believe that the decision by NICE to raise its cost per QALY
threshold for end of life drugs is both inequitable and an inefﬁ-
cient use of resources” [31]. And the majority of NICE Citizen’s
Council members were against “special consideration for treat-
ments that are life-extending” (65% or 19/29 members against)
[32]. Justiﬁcation for the existence of the Cancer Drugs Fund, where
cancer was  prioritised over other disease states, was  not found
in patient and professional interviews. Although the majority of
values elicited from patient and professional participants in these
qualitative interviews do not represent values that justify the EoL
criterion, a minority of participants agreed with the prioritisation ofhat’s fair to an individual is not always fair to a popula-
ionals using the Cancer Drugs Fund. Health Policy (2019),
the EoL, and therefore, in principle, the EoL criterion. More research
needs to be done focusing on this issue- eliciting more informa-
tion about quality of life perceptions at EoL and enabling people to
understand the costs.
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. Conclusion
The conﬂicting desire to ‘do everything’ for the individual,
hile being ‘fair’ to the population was a sentiment expressed by
rofessional and patient participants -the majority of whom felt
ncomfortable that cancer was being given special consideration in
he CDF. Although there was limited support for the current imple-
entation of the NICE EoL criterion, conﬂicting views between
hose who perceived that the time at the end of life may  have more
alue- and those that did not - raise signiﬁcant challenges for policy
akers. Better understanding of the experiences of patients with
ncurable cancer and their professionals, in relation to quality of life
t the end of life over simply time at the end of life, may  be needed
o help inform future policy making.
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